|
Real-time
Euronext Bruxelles
13:02:41 07/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 202.10 EUR | -0.10% |
|
-1.41% | -15.26% |
| 09-30 | Merck's experimental skin disease drug succeeds in mid-stage study | RE |
| 09-29 | UCB Presents Data From Innovative Myasthenia Gravis Portfolio At AANEM Annual Meeting And MGFA Scientific Session | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| UCB | Biopharmaceuticals | -0.49% | -1.85% | -15.63% | -20.72% | +107.65% | 43.45B |  | | |
- Stock Market
- Stocks
- UCB Stock
- Charts UCB
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
